Drug
Talfirastide clinical trials
Also written TXA127 and Angiotensin-(1-7).
Keep track of what changes. Save the talfirastide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 20
Tarix Pharmaceuticals (8) · University of Arizona (4) · Milton S. Hershey Medical Center (3) · Amy Arnold (2) · Erasme University Hospital (2) · Wake Forest University Health Sciences (2) · Constant Therapeutics LLC (2) · Sean Collins (1)
Often tested with
Tested in the same studies.
Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH (1) · Fostamatinib (1) · Filgrastim (1)
Studies
Open first, then newest update. How each study uses talfirastide is read from its arms, and is right about nine times in ten.
Testing it · 31
- Cardiovascular Effects of Angiotensin-(1-7) in Obesity HypertensionRecruitingEarly Phase 1Milton S. Hershey Medical CenterNCT06482853Written as Angiotensin-(1-7)
- Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain InjuryRecruitingPhase 1/2University of ArizonaNCT06282965Written as Angiotensin (1-7)
- Metabolic Effects of Angiotensin-(1-7)RecruitingPhase 1Vanderbilt UniversityNCT02646475Written as Angiotensin-(1-7)
- TXA127 in Non-Ambulant Patients With DMD CardiomyopathyRecruitingPhase 2Constant Therapeutics LLCNCT06013839Written as talfirastide
- Phase 2 Study of TXA127 in Post-ischemic Stroke PatientsRecruitingPhase 2Constant Therapeutics LLCNCT06135103Written as talfirastide
- Angiotensin-(1-7) and Energy Expenditure in Human ObesityCompletedEarly Phase 1Amy ArnoldNCT03777215Written as Angiotensin-(1-7)
- Angiotensin-(1-7) Cardiovascular Effects in AgingTerminatedEarly Phase 1Milton S. Hershey Medical CenterNCT05301192Written as Angiotensin-(1-7)
- Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure PatientsSuspendedPhase 2University of ArizonaNCT03159988Written as Angiotensin-(1-7)
- Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABGTerminatedPhase 2University of ArizonaNCT03252093Written as Angiotensin-(1-7)
- Novel Experimental COVID-19 Therapies Affecting Host ResponseCompletedPhase 2/3Sean CollinsNCT04924660Written as TXA127
- Angiotensin 1-7 in Obesity HypertensionTerminatedEarly Phase 1Amy ArnoldNCT03604289Written as Angiotensin-(1-7)
- Angiotensin-(1-7) in Peripheral Arterial DiseaseTerminatedEarly Phase 1Milton S. Hershey Medical CenterNCT03240068Written as Angiotensin 1-7
- TXA127 for the Treatment of Severe COVID-19CompletedPhase 2Columbia UniversityNCT04401423Written as TXA127
- Biomarker Study: Heart Failure Patients at RiskStatus unknownPhase 1/2University of ArizonaNCT05336175Written as Angiotensin 1-7
- Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized PatientsWithdrawnPhase 1/2Stanford UniversityNCT04570501Written as Angiotensin-(1-7)
- Use of Angiotensin-(1-7) in COVID-19CompletedPhase 1/2Erasme University HospitalNCT04633772Written as Angiotensin-(1-7)
- Angiotensin-(1,7) Treatment in COVID-19: the ATCO TrialStatus unknownPhase 2/3Erasme University HospitalNCT04332666Written as Angiotensin 1-7
- Angiotensin 1-7 as a Therapy in the Treatment of COVID-19Status unknownPhase 2Rambam Health Care CampusNCT04605887Written as Angiotensin 1-7
- Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic FailureTerminatedEarly Phase 1Vanderbilt University Medical CenterNCT02591173Written as Angiotensin-(1-7)
- Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma PatientsTerminatedPhase 2Tarix PharmaceuticalsNCT01121120Written as TXA127
See all 31 studies that test talfirastide →
Given in every arm · 1 — talfirastide is usual care beside what is tested
Codes
What other systems call talfirastide · ClinicalTrials.gg INT004150
- MeSH (NLM) C118790angiotensin I (1-7)Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) IJ3FUK8MOFTALFIRASTIDEConfirmed FDA, NLM
- NCI Thesaurus C68962TalfirastideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C118790 | angiotensin I (1-7) | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | IJ3FUK8MOF | TALFIRASTIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C68962 | Talfirastide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.